This website uses cookies

Cookies are small text files that can be used by websites to make a user's experience more secure and to analyze traffic to the site. We use cookies for the following purposes:

- Necessary: Cookies are required to access secure areas of the website and to provide important platform notifications. The site cannot function properly without these cookies
- Statistics: Cookies are used to track device information anonymously to better understand how visitors interact with the website.

This notice applies to the following domains:

An Implementation of Vendor-Neutral Multi-Attribute Method (MAM)

Multi-Attribute Method (MAM) has been gaining more attention from regulatory bodies and industry. Reliance on mass spectrometry MAM offers the ability to provide insight and clarity into the profile of drug sequence, its variant profile, and susceptibility under various stress conditions. But, with growing interest in MAM, what are the best ways to implement MAM in your laboratory?

In this webinar, Ben Niu, Ph.D., Scientist at MedImmune, will share how he created a vendor-neutral MAM workflow to monitor multiple molecule attributes, perform quantitation and generate reports to support drug development in multiple studies. He will also show how to utilize MAM for a peptide mapping method development and optimization. Ben will draw on his mass spectrometry experience in automating characterization/ method development of therapeutic proteins

Attend this webinar to learn:

How to establish MAM in your lab
How to monitor multiple molecule attributes
How to manage the challenges of MAM analysis throughout the entire workflow: sample preparation, chromatography, MS data acquisition
How to manage the unique challenges of MAM data analysis and reporting

Ben Niu, Ph.D.
Scientist / Characterization Lead
MedImmune, A member of AstraZeneca
Michelle English, Ph.D.
Customer Success Scientist
Protein Metrics Inc.

Already Registered? Log In Now

Complete this form to enter the webcast.
(* indicates required field)